Gilead Sciences vs ImCheck Therapeutics
Gilead Sciences vs ImCheck Therapeutics, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Gilead Sciences is on Not scored yet and ImCheck Therapeutics on 60/100.
Where each one leads
Gilead Sciences
- agent readiness: 41/100 against 34/100
- domain rating: 82/100 against 37/100
- headcount: 14,616 against 47
- LinkedIn following: 818,832 against 11,647
ImCheck Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Gilead Sciences | ImCheck Therapeutics |
|---|---|---|
| What it is | Biopharmaceutical company focused on developing and commercializing innovative medicines. | ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies. |
| Category | Biotech, MedTech, HealthTech, Drug Discovery | Biotech, MedTech, HealthTech, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Biotech | Biotech |
| Founded | 1987 | 2015 |
| Headquarters | Foster City, United States | Marseille, France |
| Status | Active | Active |
Size, funding and growth
| Measure | Gilead Sciences | ImCheck Therapeutics |
|---|---|---|
| Employees | 14,616 | 47 |
| Open roles | 100 | Not published |
| Total funding | Not published | $164M |
| LinkedIn followers | 818,832 | 11,647 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Gilead Sciences | ImCheck Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | Not published | 60/100 |
| Traction | Not published | 57/100 |
| Team | Not published | 70/100 |
| Community | Not published | 15/100 |
| Search visibility | Not published | 22/100 |
| Quality | Not published | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (41/100) | F (34/100) |
| Domain ratingLink authority, 0-100 | 82/100 | 37/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Gilead Sciences | ImCheck Therapeutics |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CDN | Cloudflare | Not detected |
| Frameworks | Tailwind CSS, Bootstrap | Jquery, Tailwind CSS, Bootstrap |
| Analytics | Google Tag Manager | Google Analytics 4 |
Gilead Sciences vs ImCheck Therapeutics: common questions
Which is better, Gilead Sciences or ImCheck Therapeutics?
On our 0-100 score ImCheck Therapeutics rates higher (60/100 against Not scored yet). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do Gilead Sciences and ImCheck Therapeutics compare on the numbers?
Gilead Sciences leads on agent readiness (41/100 against 34/100), domain rating (82/100 against 37/100), headcount (14,616 against 47), LinkedIn following (818,832 against 11,647).
Read the full Gilead Sciences review and pricing or the ImCheck Therapeutics review and pricing. You can also browse other Gilead Sciences alternatives we track.